All In Biotech

Drug Trial Radar · NCT02631070

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions.

Last checked: Nov 20, 2026Latest source record: Dec 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 229 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

229

Actual

Start

Feb 9, 2016

Primary completion

Jun 18, 2019

Study completion Nov 26, 2020

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
First posted
Dec 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in participants with anemia due to the Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate MDS with ring sideroblasts who require red blood cell (RBC) transfusions.

Conditions

  • Myelodysplastic Syndromes

Interventions

  • LuspaterceptDrug

  • PlaceboOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24Time frame: From Week 1 through Week 24 of study treatment

Locations

74 sites in 11 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Center

    Stanford, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Ochsner Medical Institutions

    New Orleans, Louisiana

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Columbia-Presbyterian Medical Center

    New York, New York

  • Montefiore Medical Center Albert Einstein Cancer Center

    The Bronx, New York

  • Gabrail Cancer Center

    Canton, Ohio

  • Cleveland Clinic Taussig Cancer Institute

    Cleveland, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Algemeen Ziekenhuis Klina

    Brasschaat, Belgium

  • AZ Sint-Jan AV Brugge

    Bruges, Belgium

  • UZ Brussels

    Brussels, Belgium

  • Grand Hopital de Charleroi

    Charleroi, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Cliniques Universitaires UCL de Mont-Godine

    Yvoir, Belgium

  • Tom Baker Cancer Center

    Calgary, Alberta, Canada

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • CHU d'Angers

    Angers, France

  • CHU Hotel

    Grenoble, France

  • CHRU de Lille-Hopital Claude Huriez Service des Maladies du Sang

    Lille, France

  • Institut Paoli Calmettes

    Marseille, France

  • CHU de Nice Archet I

    Nice, France

  • Hopital Saint Louis

    Paris, France

  • Hopital Haut Leveque

    Pessac, France

  • Centre hospitalier Lyon Sud Hematologie

    Pierre-Bénite, France

  • Hopital civil

    Strasbourg, France

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, France

  • Hopital Bretonneau

    Tours, France

  • Universitatsklinikum Bonn

    Bonn, Germany

  • Universitatsklinikum Carl Gustav Carus an der TU Dresden

    Dresden, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Marien Hospital

    Düsseldorf, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.